BBS Faculty Member - Shobha Vasudevan

Shobha Vasudevan

Department of Medicine

Massachusetts General Hospital Cancer Center
Richard B Simches Research Center
185 Cambridge Street, CPZN 4202/4100
Boston, MA 02114
Tel: 617-643-3143
Fax: 617-643-3170
Email: vasudevan.shobha@mgh.harvard.edu
Lab Members: 3 postdoctoral fellows, 1 technician, 1 undergraduate student
Visit my lab page here.



The Vasudevan laboratory focuses on the role of RNA binding proteins and noncoding RNAs called microRNAs in cancer cells. Tumors demonstrate heterogeneity, harboring a small proportion of assorted quiescent cells that switch from rapid proliferation—characteristic of other cancer cells—to a specialized, reversibly arrested state that decreases their susceptibility to chemotherapy. Quiescent cancer cells can resist conventional therapeutics and contribute to cancer recurrence, resuming proliferation and cancerous growth upon chemotherapy removal. Previous data revealed that microRNAs, noncoding RNAs that control vital genes in cancer and growth, are important for the persistence of quiescent cancer cells. The primary goal of our research program is to characterize the expression and roles of regulatory noncoding RNAs and AU-rich elements (AREs) in quiescence and tumor progression. A complementary focus is to investigate the regulation of noncoding RNAs and AREs in response to quiescent conditions in tumors, stem cells and germ cells. Our goal is to develop a greater understanding of the versatile roles of regulatory RNAs in cancer as a basis for developing new drug therapies.

AU-rich elements (AREs) are highly conserved mRNA 3’-untranslated region (UTR) regulatory elements while microRNAs are small noncoding RNAs that target distinct 3’UTR sites and control post-transcriptional gene expression of clinically relevant messages, including those of cytokines and potent growth factors. MicroRNAs, like AREs, are known post-transcriptional regulators in cell proliferation, development and death. Their deregulation leads to rapid and dramatic changes in expression levels promoting a broad range of critical effects, including tumor growth, chemoresistance, metastasis, recurrences, leukemias, lymphomas and developmental disorders.

The primary goal of our research program is to investigate the underlying mechanisms of gene expression control of critical, cancer-associated cytokine and growth factor genes by noncoding RNAs, microRNAs and AREs, as well as their interactions and synergisms with RNA binding protein complexes (RNPs) in response to quiescent conditions in tumors that lead to tumor progression and recurrence. An associated direction is to investigate the regulation of expression and function of regulatory noncoding RNAs and RNPs by distinct tumor-associated conditions, using cancer cell lines, stem cells and
Xenopus laevis germ cells. An important focus of our research is to functionally characterize the selective interactions between regulatory noncoding RNAs, RNPs, and their mRNA targets that encode for critical growth and cell state regulators, and develop specific therapeutic approaches against tumor resistance and recurrence.

Several studies indicate that cells that survive clinical therapy include dormant, quiescent G0-like cells, observed as a small—but clinically relevant —population in leukemias and in several solid tumors associated with poor survival rates. Quiescence or G0 is a unique, adaptive, nonproliferating state that provides an advantageous escape from harsh situations and chemotherapy, allowing cells to evade permanent outcomes of tumor-negative environments such as senescence, differentiation or apoptosis. Instead, the cell is suspended reversibly in an assortment of transition phases that retain the ability to return to proliferation and contribute to tumor heterogeneity, resistance and recurrence. Quiescence involves gene expression reprogramming, upregulating those mRNAs and regulatory RNAs—including specific microRNAs—required for survival and persistence in the G0 state. The key finding of our studies on cytokine and growth factor gene expression, which forms the basis of our research program, is that AREs, microRNAs and RNPs are transformed by such cellular conditions to alter expression patterns of specific, clinically important genes. We further identified post-transcriptional effectors associated with these RNAs under distinct conditions by developing an in vivo crosslinking-coupled affinity purification method to purify endogenous RNP complexes. These findings opened a novel, unexplored area of research into gene expression control in response to tumor-associated conditions by highly potent RNA regulators. These investigations have major implications for understanding gene expression that contributes to tumor progression, resistance and recurrence.

The lab has four core directions:
1. To functionally characterize microRNAs and specific noncoding regulatory RNAs and identify their associated cofactors and target mRNAs that control expression of clinically important cytokines, cancer and cell state regulators, using previously developed in vivo crosslinking coupled affinity purification methods and confirmatory assays.
2. To investigate the mechanism of gene expression control and interconnections of the identified RNA regulators, AREs, microRNA target sites and RNPs.
3. To elucidate the regulation of expression and function of noncoding RNAs, AREs and RNPs by specific tumor-associated conditions.
4. To characterize the selective interactions between small regulatory RNAs and their mRNA targets in order to develop antisense manipulations of these interactions as specific therapeutic approaches. These studies should lead to a greater understanding of the versatile role of regulatory small noncoding RNAs in the pathogenesis of cancers and to novel approaches in RNA-based therapeutic applications.



Last Update: 6/20/2014



Publications

Liu M, Roth A, Yu M, Morris R, Bersani F, Rivera MN, Lu J, Shioda T, Vasudevan S, Ramaswamy S, Maheswaran S, Diederichs S, Haber DA. (2013). The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes & Dev: 27(23):2543-8.

Vasudevan, S. (2012). Functional validation of microRNA-target RNA interactions. Methods. 58(2):126-34, http://dx.doi.org/10.1016/j.ymeth.2012.08.002

Truesdell, SS, Mortensen, RD, Seo, M, Schroeder, J, Lee JH, LeTonqueze, O and
Vasudevan, S. (2012). MicroRNA-mediated Upregulation in Immature oocytes and G0 human cells involves a nuclear AGO complex. Sci. Rep.;2:842. doi: 10.1038/srep00842.

Chen, A-J, Paik, J-H, Zhang, H, Shukla, SA, Mortensen, RD, Hu, J, Ying, H, Hu, B, Hurt, J, Farny, N, Dong, C, Xiao, Y, Wang, YA, Silver, PA, Chin, L,
Vasudevan, S and DePinho, RA. Star RNA-binding protein, Quaking, suppresses cancer via stabilization of specific miRNA. Genes Dev. 26(13):1459-72, 2012.

Mortensen RD, Serra M, Steitz JA,
Vasudevan S. Posttranscriptional activation of gene expression in Xenopus laevis oocytes by microRNA-protein complexes (microRNPs). Proc Natl Acad Sci U S A. 108 (20):8281-6, 2011 May 17.

Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007 Dec 21; 318(5858):1931-4.

Vasudevan S, Steitz JA. AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell. 128(6):1105-18, 2007 Mar 23.



© 2013 by the President and Fellows of Harvard College